SEC Form 4 · accession 0001995218-26-000013
Lexeo Therapeutics, Inc. · LXEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Nolan Townsend
Officer — Chief Executive Officer · Director
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 6:47 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001907108
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | A | 67,000 | $0.00 | A | 403,764 | D | |
| Common StockF2,F3 | Jul 1, 2026 | S | 25,947 | $4.48 | D | 377,817 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a sale to cover tax obligations on the release of performance Restricted Stock Units ("RSUs").
- F2This transaction was executed in multiple trades at prices ranging from $4.3402 to $4.7507. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3Includes 252,130 RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.